Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology.
Agostinetto E, Bruzzone M, Hamy AS, Kim HJ, Chiodi C, Bernstein-Molho R, Linn S, Pogoda K, Carrasco E, Derouane F, Bajpai J, Nader-Marta G, Lopetegui-Lia N, Partridge AH, Cortesi L, Rousset-Jablonski C, Giugliano F, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Aguilar Y Mendez D, De Marchis L, Borea R, Puglisi F, Pistelli M, Kufel-Grabowska J, Di Rocco R, Mariamidze E, Atzori F, Kourie HR, Popovic L, de Azambuja E, Blondeaux E, Lambertini M. Agostinetto E, et al. Among authors: renaud t. ESMO Open. 2024 Oct;9(10):103714. doi: 10.1016/j.esmoop.2024.103714. Epub 2024 Sep 16. ESMO Open. 2024. PMID: 39288653 Free PMC article.
Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model.
Willemin ME, Gong J, Hilder BW, Masterson T, Tolbert J, Renaud T, Heuck C, Kane C, De Zwart L, Girgis S, Ma X, Ouellet D. Willemin ME, et al. Among authors: renaud t. Target Oncol. 2024 Nov;19(6):965-979. doi: 10.1007/s11523-024-01093-6. Epub 2024 Sep 16. Target Oncol. 2024. PMID: 39285155 Free PMC article. Clinical Trial.
Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Ye JC, Biran N, Nair S, Lin X, Qi K, Londhe A, Ammann E, Renaud T, Kane C, Parekh T, Gray K, Peterson S, Costa LJ. Ye JC, et al. Among authors: renaud t. Clin Lymphoma Myeloma Leuk. 2024 Aug 13:S2152-2650(24)00295-7. doi: 10.1016/j.clml.2024.08.003. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39271448
Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma.
Catamero D, Ray C, Purcell K, Leahey S, Esler E, Rogers S, Hefner K, O'Rourke L, Gray K, Tolbert J, Renaud T, Patel S, Hannemann L, Shenoy S. Catamero D, et al. Among authors: renaud t. Semin Oncol Nurs. 2024 Oct;40(5):151712. doi: 10.1016/j.soncn.2024.151712. Epub 2024 Aug 17. Semin Oncol Nurs. 2024. PMID: 39155155 Free article. Review.
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers.
Arecco L, Bruzzone M, Bas R, Kim HJ, Di Meglio A, Bernstein-Molho R, Hilbers FS, Pogoda K, Carrasco E, Punie K, Bajpai J, Agostinetto E, Lopetegui-Lia N, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, Curigliano G, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Couch FJ, Dieci MV, Matikas A, Rozenblit M, Aguilar-Y Méndez D, De Marchis L, Puglisi F, Fabi A, Graff SL, Witzel I, Rodriguez Hernandez A, Fontana A, Pesce R, Duchnowska R, Pais HL, Sini V, Sokolović E, de Azambuja E, Ceppi M, Blondeaux E, Lambertini M. Arecco L, et al. Among authors: renaud t. Ann Oncol. 2024 Sep;35(9):792-804. doi: 10.1016/j.annonc.2024.06.009. Epub 2024 Jun 20. Ann Oncol. 2024. PMID: 38908482 Free article.
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.
Chari A, Krishnan A, Rasche L, Ye JC, Garfall A, Popat R, Lipe B, Qin X, Campagna M, Masterson T, Tomlinson C, Hilder B, Tolbert J, Renaud T, Smit MD, Gray K, Kane C, Heuck C, van de Donk NWCJ. Chari A, et al. Among authors: renaud t. Clin Lymphoma Myeloma Leuk. 2024 Oct;24(10):665-693.e14. doi: 10.1016/j.clml.2024.05.003. Epub 2024 May 15. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38871558 Free article. Clinical Trial.
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, Cornax I, Vishwamitra D, Gray K, Hilder B, Tolbert J, Renaud T, Masterson T, Heuck C, Kane C, Verona R, Moreau P, Bahlis N, Chari A. Rodriguez-Otero P, et al. Among authors: renaud t. Blood Cancer J. 2024 Mar 6;14(1):40. doi: 10.1038/s41408-024-01018-6. Blood Cancer J. 2024. PMID: 38448422 Free PMC article. No abstract available.
55 results